Abstract Herein, we report our examination of the antibreast cancer activity of a novel synthetic compound, 7-(benzylamino)-1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one (BA-TPQ). This agent is an analog of a naturally occurring marine compound, and was found to be the most active out of more than 40 related compounds. We investigated the in vitro activity of BA-TPQ on the survival, proliferation, and apoptosis of breast cancer cells using the MTT and BrdUrd assays, and Annexin/Annexin-PI staining and flow cytometry. The in vivo anti-cancer effects of BA-TPQ were evaluated in xenograft models of breast cancer. Finally, the mechanisms of action of the compound were also assessed by cDNA microarrays, RT-PCR and Western blotting. In a dose-dependent manner, BA-TPQ inhibited cell growth and induced apoptosis and cell cycle arrest in human MCF-7 and MDA-MB-468 breast cancer cells in vitro, and showed in vivo efficacy in mice bearing MCF-7 or MDA-MB-468 xenograft tumors. We demonstrated that BA-TPQ modifies the expression of numerous molecules involved in cell cycle progression and apoptosis. Similar changes in protein expression were observed in vitro and in vivo, as determined by examination of cells and excised xenograft tumors. Our preclinical data indicate that BA-TPQ is a potential therapeutic agent for breast cancer that has multiple hormone-, Her2-, and p53-independent mechanisms of action, providing a basis for further development of the compound as a novel anticancer agent.
Introduction
Despite efforts made to improve diagnostic capabilities using new instrumentation and biomarkers, breast cancer is still often diagnosed in (or progresses to) advanced, metastatic, and drug-resistant stages. While patients who are diagnosed early, and especially those with hormone receptor (and Her2) positive disease, have an excellent prognosis [1, 2] , those with metastatic disease or hormoneor triple-negative tumors, have dramatically lower survival rates [2, 3] . These cancers are both intrinsically more difficult to treat due to the fact they have fewer targets, and they have also often developed additional mutations that make them resistant to conventional chemotherapy [4, 5] . There is a need for effective new therapeutic agents for advanced cancers.
Although ''rationally-targeted'' therapies (e.g., Herceptin and Gleevec) have promise for certain cancers, these agents are effective in only a percentage of patients, and are generally ineffective against recurrent or metastatic tumors due to resistance to the agent acquired during its initial use [6] . Although it runs counter to the focus of recent research, the development of novel, broadly effective/ multi-targeted therapeutic agents can lead to improved anti-tumor efficacy. Moreover, by avoiding the need to combine several agents, the use of a single multi-faceted agent could also lead to a decrease in toxicity and adverse drug interactions for the patient.
Microbe-, plant-, and animal-based natural products are being explored as novel therapeutics or complementary and alternative medicines. These agents frequently lack a single molecular target. For example, genistein has been reported to exert its cancer preventive and therapeutic effects through several mechanisms, including inhibition of tyrosine kinase activity, agonism or antagonism of steroid receptors, inhibition of oncogenes, inhibition of angiogenesis, and anti-oxidant activity [7] . Other natural products have been shown to have a similar range of activities [8] [9] [10] [11] . In fact, it may be that these compounds are effective for cancer prevention and therapy precisely because they act through multiple mechanisms of action.
We have been evaluating novel synthetic iminoquinone compounds based upon a natural product scaffold [12] . These compounds have potent cytotoxic activity against a variety of human cancer cell lines, including drug-resistant breast cancer cells [13] . Among more than 40 analogs that have been synthesized, 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (BA-TPQ) showed potent in vitro activity against several human cancer cell lines, including the greatest activity against breast cancer cells. The structure of BA-TPQ is given in Fig. 1a . In accordance with the studies of other natural product-based agents, the iminoquinone analogs exert a variety of anticancer activities, including inhibition of topoisomerase II [14] , inhibition of cell survival/proliferation [13] , inhibition of oncogene expression [15] , and inhibition of androgen receptor expression [15] . As preliminary studies indicated that BA-TPQ was highly effective against breast cancer cells [13, 14] , the present study examined the compound's in vivo anti-breast cancer activity, and further examined the mechanism(s) by which it exerts anti-cancer effects in vitro and in vivo.
Materials and methods

Test compound
Approximately 300 mg of BA-TPQ was synthesized for the experiments reported in this article. The purity of the compound was greater than 99.0%, based on 1 H-NMR, 13 C-NMR, and mass spectral analyses. These spectra were consistent with the structure of BA-TPQ (Fig. 1a) In order to generate the MCF-7 p53 knockdown (KD) cells, parental MCF-7 cells were transfected with an expression plasmid containing a siRNA directed against p53. In order to construct the short interfering RNA (siRNA) expression plasmids under the control of the U6 promoter, selected oligonucleotides were cloned into pBabe-U6 at BamHI and XhoI sites for expression of siRNA in vivo. One pair of siRNA oligonucleotides from p53 were synthesized and cloned into pBabe-U6. The target sequence of the oligonucleotides for p53 knockdown (derived from the p53 gene) was 5 0 -GACTCCAGTGGTAATCTAC. All chemicals and solvents used were of the highest analytical grade available. Anti-human Bax (N-20), Bcl-2 (100), Cdk2 (M2), Cdk4 (H-22), Cdk6 (C-21), Cyclin D1 (DCS-6), E2F1 (KH95), MDM2 (SMP14), PARP1 (H-250), p21 (C19), and p27 (C19) antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The antihuman p53 (Ab-6) antibody was from EMD Chemicals, Inc. (Gibbstown, NJ), and the Caspase-3 (9662), Caspase-8 (9746), and Caspase-9 (9502) antibodies were from Cell Signaling Technology, Inc (Danvers, MA).
Cell lines and culture
Human breast cancer and non-malignant epithelial cells were obtained from the American Type Culture Collection (Rockville, MD), and were cultured according to their instructions. The MCF-7 cells positive for the pBabe-U6-p53 vector were selected, and grown in the same media as parental MCF-7 cells, and expression of the vector was maintained with puromycin (0.5 lg/mL; Sigma, St. Louis, MO).
Assays for cell viability, apoptosis, and cell cycle progression
The effects of test compounds on human cancer cell growth, apoptosis, and cell cycle progression were determined using MTT, Annexin V-FITC, and propidium iodide as previously reported [16] . In brief, 4-5 9 10 3 cells per well were exposed to the test compounds (0-1.0 lM) for 72 h for MTT assay. In order to assess apoptosis using the apoptosis detection kit from BioVision (Mountain View, CA), 2-3 9 10 5 cells were exposed to the test compound (0, 0.1, 0.5, or 0.75 lM) and incubated for 48 h prior to analysis. Cells that were positive for Annexin V-FITC alone (early apoptosis) and Annexin V-FITC and PI (late apoptosis) were counted. In order to determine the effects of the compound on the cell cycle, cells (2-3 9 10 5 /well) were exposed to the test compound (0, 0.1, 0.5, or 0.75 lM) and incubated for 24 h prior to analysis. Cells were then trypsinized, washed with PBS, and fixed in 1.5 ml of 95% ethanol at 4°C overnight, followed by incubation with RNAse and staining with propidium iodide (Sigma). The DNA content was determined by flow cytometry.
Human breast cancer xenograft models and animal treatment
The animal protocol was approved by the Institutional Animal Use and Care Committee of the University of Alabama at Birmingham. Female athymic pathogen-free nude mice (nu/nu, 4-6 weeks) were purchased from Frederick Cancer Research and Development Center (Frederick, MD). In order to establish MCF-7 human breast cancer xenografts, each of the female nude mice was first implanted with a 60-day sc slow release estrogen pellet (SE-121, 1. 6 cells (total volume 0.2 mL) were injected s.c. into the left inguinal area of the mice. All animals were monitored for activity, physical condition, body weight, and tumor growth. Tumor size was determined by caliper measurement in two perpendicular diameters of the implant every other day. Tumor weight (in g) was calculated by the formula, 1/2a 9 b 2 where ''a'' is the long diameter and ''b'' is the short diameter (in cm).
The animals bearing human cancer xenografts were randomly divided into various treatment groups and a control group (7-10 mice/group). The untreated control group received the vehicle only. For the MCF-7 xenograft model, BA-TPQ was dissolved in PEG400:ethanol:saline (57.1:14.3:28.6, v/v/v), and was administered by intraperitoneal (i.p.) injection at doses of 5 and 10 mg/kg/d, 3 d/ wk for 3 weeks. For the MDA-MB-468 xenograft model, BA-TPQ was administered by i.p. injection at doses of 1 mg/kg/day and 10 mg/kg/day, 5 days/week for 6 weeks. At the end of the experiments, xenograft tumors were removed and homogenized, and the resulting supernatants were used for Western blotting analysis of several proteins.
Western blot analysis
In the in vitro studies, cells were exposed to various concentrations of BA-TPQ for 24 h. In vivo tissue homogenates were prepared in RIPA buffer (100 mg tumor tissue/ 1 ml RIPA) for immunoblotting analysis as reported previously [16] .
Microarrays
Affymetrix GeneChipÒ Human Gene 1.0 ST (HuGene-1_0-st-v1) arrays were used for comprehensive analysis of genome-wide expression. Each of the 28,869 known genes was represented on the array by approximately 26 probes spread across the full length of the gene. The GeneChip analysis was carried out at by the Gene Expression Shared Facility located in the Heflin Center for Human Genetics at UAB. The quality of each RNA sample was determined by analysis on a 2100 Agilent Bioanalyser prior to RNA labeling. Detailed GeneChip analysis procedures are presented in the Manufacturer's GeneChip Expression Technical Manual (Affymetrix, Santa Clara, CA). Briefly, 100 ng of total RNA from each sample was used to generate double stranded cDNA by linear amplification using random primer linked-T7 primers and reverse transcriptase. Subsequently, biotinlabeled cRNA was synthesized by in vitro transcription (IVT) using the WT-Amplification Reagents for whole transcript labeling (Affymetrix) followed by cRNA fragmentation and preparation of hybridization cocktail. The arrays were hybridized overnight at 45°C, and then washed, stained, and scanned the next day. GeneChip data were extracted, normalized, and summarized using the robust multi-average (RMA) method included in the Affymetrix Expression Console.
RNA extraction and RT-PCR Cells were exposed to 0 or 0.5 lM BA-TPQ for 16 h, then were resuspended in 1 ml of Trizol reagent (Carlsbad, CA), passed several times through a pipette to form a homogenous lysate, and incubated at room temperature for 5 min. Chloroform (0.2 ml) was added to each tube, mixed well by shaking vigorously for 15 s, incubated at room temperature for 2-3 min, and centrifuged at 13,0009g for 10 min at 4°C. The aqueous phase was collected in a fresh tube. Total RNA was precipitated with 500 lL of isopropanol, washed with 75% ethanol for 2 min, and resuspended in DEPC-treated water. RNA yields and purity were determined spectrophotometrically by measuring the absorbance of aliquots at 260 and 280 nm. RNA integrity was checked by visualizing the relative intensities of the 28S and 18S rRNA separated by agarose gel electrophoresis in the presence of formaldehyde. RNA was stored at -80°C until cDNA synthesis using the SuperScript RT-PCR kit from Invitrogen. The sequence of the sense (S) and antisense (AS) primers used for RT-PCR are given in Table 1 .
Statistical and bioinformatics analyses
The majority of quantitative data in the present study are reported as means ± SD from at least three independent experiments. One-way ANOVA was used to test differences for single group analysis, followed by Tukey's multiple comparisons. Two-way ANOVA was used for grouped analysis of differences followed by Bonferroni post-tests.
Statistical and bioinformatics analysis of microarray data were conducted using the software packages ArrayAssist Enterprise, PathwayAssist (Stratagene/Agilent, Santa Clara, CA), and GeneSpring (Agilent, Santa Clara, CA). Briefly, the raw GeneChip files from GeneChip Operating Software (GCOS, Affymetrix, CA) were uploaded, background-subtracted, variance-stabilized, and normalized using the GC-RMA method [17] . Additional filters, such as presence (P) and absence (A) call, were applied for quality control purposes. The control (or otherwise indicated) group was used as a baseline to calculate the intensity ratio/fold changes of the treated versus the control group. The ratio was log2-transformed before further statistical analysis. The P values were obtained by an unpaired t-test assuming unequal variance.
Results
BA-TPQ has in vitro anticancer activity
Inhibition of cancer cell growth
Three human breast cancer cell lines (MCF-7/p53 wt; MCF-7/p53 KD and MDA-MB-468/p53 mt) and one ''normal'' (immortalized but non-malignant) breast epithelial cell line (MCF-10A) were cultured with the compound at concentrations ranging from 0-1.0 lM for 72 h, and cell viability was determined. The MCF-7 and MDA-MB-468 cell lines were selected because both of them represent advanced breast cancers, but are of different backgrounds with regard to genomic classification (MCF-7 are luminal, MDA-MB-468 are basal-like; [18] ), reflecting their differences in expression of a number of genes, including the estrogen receptor and p53. This allows for an initial assessment of the activity of the compound against diverse breast cancers.
The inhibitory effects of the compound on cell growth are illustrated in Fig. 1b . BA-TPQ showed a strong dosedependent cell growth inhibition, with significant (P \ 0.01) activity beginning at the 0.01 and 0.1 lM concentrations for the MCF-7 wt and MDA-MB-468 cells, respectively, and at the 0.1 lM concentration (P \ 0.05) for the MCF-7 p53 KD cells. In fact, there was a 94.3% (P \ 0.01), 81.8% (P \ 0.01) and 99.6% (P \ 0.01) inhibition of cell viability at 1 lM in the different cell lines, respectively. Although the MCF-10A non-malignant breast epithelial cells demonstrated a significant (P \ 0.05) decrease in viability at the 0.1 lM concentration, they were less sensitive to the inhibitory effects of BA-TPQ than the breast cancer cells, never showing any significant increase in cell growth inhibition over that observed at the 0.1 lM concentration. Moreover, by the 0.1 lM concentration, there were significant (P \ 0.01) differences in the sensitivity of all three of the cancer cells to the compound compared to the ''normal'' MCF-10A cells.
Induction of apoptosis in human breast cancer cells
As illustrated in Fig. 1c , BA-TPQ induced apoptosis in a dose-dependent manner in all three cell lines. In the p53 wt MCF-7 and p53 KD MCF-7 cells, a 0.75-lM concentration of BA-TPQ increased the apoptotic index 16-fold and 6-fold higher than that seen in control (vehicle-treated) cells, respectively. In the MDA-MB-468 cells, BA-TPQ led to a 4.5-fold increase in apoptosis at 0.75 lM (P \ 0.01). Although all of the cell lines showed a significant increase in apoptosis beginning at the 0.5 lM concentration (P \ 0.05), the MCF-7 cells (both wt and p53 KD) were significantly more sensitive (P \ 0.01) than the MDA-MB-468 cells.
BA-TPQ exposure results in cell cycle arrest
The effects of BA-TPQ on cell cycle distribution were not the same among the tested cell lines (Fig. 1d) . At a concentration of 0.75 lM, BA-TPQ induced arrest in the G1 phase (P \ 0.01) in MCF-7 cells; in MCF-7 p53 KD and MDA-MB-468 cells, it induced arrest in the S-phase (P \ 0.01). These differences are likely due to the different backgrounds of p53 in these cells. In the p53 wt MCF-7 cells, it is likely that p53 is activated by the compound, leading to increased p21 transcription and inhibition of cyclin dependent kinases, resulting in cell cycle arrest in the G1 phase [19] . In contrast, when p53 is lacking, the compound induces arrest in the S-phase, perhaps as a result of its inhibition of Cdc25A and other cell cycle regulators, resulting in faulty dephosphorylation of cyclin E [20] .
BA-TPQ decreases the growth of xenograft tumors
In order to obtain a preliminary assessment of the in vivo anti-tumor activity of the compound, BA-TPQ was first evaluated in an MCF-7 mouse xenograft model of breast cancer. The higher dose (10 mg/kg/day, 3 days/week) inhibited MCF-7 xenograft tumor growth by about 60%
(P \ 0.01) on day 18 (Fig. 2a) , with significant differences in tumor size between the BA-TPQ-and vehicle-treated animals being observed beginning on day 6. The in vivo anticancer activity of BA-TPQ was then further investigated in the MDA-MB-468 xenograft model (Fig. 2b) . In this model, BA-TPQ was administered by i.p. injection at doses of 1 mg/kg/d or 10 mg/kg/d, 5 days/ week for 6 weeks. Even at the 1 mg/kg dose, there was considerable in vivo activity, with xenograft tumor growth being inhibited by about 46% at the end of the 6-weeks (P \ 0.01), and significant tumor growth inhibition noted beginning on day 6. In both the models, there were obvious dose-responses, with significant differences in the tumor sizes of animals in the higher and lower treatment groups occurring on days 15 (MCF-7) and 27 (MDA-MB-468). Minimal (but significant) host toxicity (followed using body weight as a surrogate marker) was observed at the 10 mg/kg dose in both the models (Fig. 2c, d ).
Determination of the mechanism(s) of action of BA-TPQ
BA-TPQ alters the expression of proteins involved in cell cycle progression and apoptosis
We next investigated the mechanism(s) of action of BA-TPQ by examining its effects on the expression level of various proteins involved in cell cycle progression and apoptosis (Fig. 3) . In MCF-7 cells, BA-TPQ increased p53 and down regulated MDM2, cyclin D1, Cdk2, Cdk4, Cdk6, and E2F1 (Fig. 3a) . Similar effects on cell cycle/proliferation-related proteins were observed in the MCF-7 p53 KD cells and MDA-MB-468 (p53 mutant) cells, indicating that the activity of BA-TPQ is p53-independent.
In order to determine the potential mechanisms responsible for BA-TPQ-induced apoptosis, the levels of Bax, cleaved PARP1, and cleaved caspases 3, 8, and 9 were analyzed. All of these apoptosis-related molecules increased following exposure of all three cell lines (MCF-7, MCF-7 p53 KD, and MDA-MB-468) to BA-TPQ (Fig. 3b) . Both caspases-8 and -9 were activated, indicating that the compound induces apoptosis through both the intrinsic and extrinsic pathways. Analysis of MCF-7 tumors collected at the end of the in vivo experiment showed that the pattern of protein expression in the treated xenograft tissues was the same as that observed in vitro (Fig. 3c) .
Microarray analysis of gene expression in MCF-7 cells following BA-TPQ exposure
In order to further examine the mechanism(s) by which BA-TPQ exerts its effects, we accomplished a gene microarray study of MCF-7 cells following exposure to the compound. Of more than 28,000 genes examined, 13 genes related to cell cycle progression/proliferation or apoptosis were up-or down-regulated by at least 3-fold (Table 2) , including E2F2, CDC25A, and SPC25 (down-regulated), and DUSP1, TNFRSF21, and DDIT4 (up-regulated). Other up-regulated genes included GADD45A, TNFRSF21, and TNFAIP3. These are related to the stress response and apoptosis, further supporting the increase in apoptosis induced by the compound. The expression of a variety of other genes related to proliferation and/or apoptosis were also modified, many by more than 2-fold ( Table 2) .
Confirmation of microarray data
Selected genes that had altered expression levels by microarray analysis were confirmed by RT-PCR. The expression levels of various genes, including DUSP1, TNFRSF21, and SPC25 were all shown to have altered mRNA expression in BA-TPQ-treated cells that correlated with the microarray findings (Fig. 4) . In all, we examined the mRNA expression of 21 different cell cycle-and apoptosis-related targets, and found that the changes in all of the mRNA levels (up/down-regulation following exposure to BA-TPQ) correlated with the results observed from the microarray studies ( Fig. 4; Table 2 ). 
Discussion
Previous studies indicated that BA-TPQ had activity against various human cancer cell lines, and that it was especially effective against breast cancer cells [13] [14] [15] . The mechanism(s) of action of BA-TPQ were not examined previously, but studies of related compounds have indicated various possible mechanisms of action for the iminoquinone analogs, including inhibition of topoisomerase II, inhibition of cell survival/proliferation, inhibition of oncogene expression, and interference with hormone receptor signaling [13] [14] [15] .
In the present study, we observed that BA-TPQ significantly decreased breast cancer cell growth, increased apoptosis and led to cell cycle arrest. BA-TPQ also decreased the growth of both MCF-7 (ER?/?, p53?/?) and MDA-MB-468 (ER-/-, p53-/-) xenograft tumors, with a 1-mg/kg dose leading to approximately 50% tumor growth inhibition (46%) in the MDA-MB-468 model after 6 weeks of treatment. Further studies to optimize the treatment schedule are needed. Additional studies of the potential of the compound for preventing and treating metastases (using an orthotopic model) would also be informative. Since there are no published reports about the pharmacokinetics, toxicity, or bioavailability of BA-TPQ or any related compounds, we have started evaluating these factors.
As a preliminary step in evaluating the mechanisms of action of BA-TPQ, we examined the expression of several proteins known to be involved in apoptosis and cell cycle regulation. In the three cell lines, there was decreased expression of various proteins, including E2F1, Bcl-2, cyclin D1, cdk2, cdk4, and cdk6, and increased expression of Bax and p53 (in the MCF-7 cells). Similar effects on protein expression were observed in excised xenograft tumors. We then made use of cDNA microarrays to further explore the activities of the compound. Using this method, we found that BA-TPQ altered the expression of a number of cell cycle regulatory and apoptosis-related genes in MCF-7 cells exposed to the compound. The changes in the mRNA level of several of these genes were then confirmed using RT-PCR.
Together, these results indicated that BA-TPQ exerts its effects primarily by inhibiting cell cycle progression and inducing apoptosis, making use of both p53-dependent and p53-independent pathways. It is also possible that the compound activates the DNA damage response, and may inhibit topoisomerase II [10] , although the effects on apoptosis and the cell cycle appear to be the most important mechanisms of action for the compound. BA-TPQ, therefore, exerts its potent anti-cancer effects through a variety of mechanisms.
This multi-faceted activity may prove to be a major benefit to use BA-TPQ and similar agents in the clinic. While ''rationally-targeted'' therapeutics have helped increase survival for some patients, these agents are generally limited in their applications to small sub-sets of patients. For example, Herceptin is only useful for 20-30% of breast cancer patients [21] , and many patients develop resistance to the drug after initial treatment [6] . In order to successfully eradicate a larger number of cancers, and especially to destroy advanced and metastatic cancers, it will be necessary to target multiple pathways. It may also be necessary to target multiple molecules/pathways in localized and early-stage disease to avoid the development of drug resistance. BA-TPQ, through its actions on the p53/MDM2 axis, p53-independent cell cycle and apoptosis-related pathways, topoisomerase inhibition, and other pathways, is likely to prevent or overcome drug resistance, and to exert potent effects against cancer cells regardless of their genetic background. Moreover, since BA-TPQ does not depend on the genetic background of the cells, it is appropriate to use against a variety of breast cancers, including triple-negative breast cancers. In summary, the observations from this study provide strong support for the use of BA-TPQ as an anti-tumor agent for human breast cancer. Further studies of the compound in comparison with its analogs, including studies of its activity against drug-resistant tumors and studies of its distribution and possible host toxicity, will increase understanding of its mode of action and contribute to the better design of future preclinical and clinical trials.
